DRUG:AU:AU-BetaShares Global Healthcare Currency Hedged (AUD)

ETF | Others |

Last Closing

USD 8.59

Change

-0.05 (-0.58)%

Market Cap

USD 0.17B

Volume

0.05M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
VAS:AU Vanguard Australian Shares

-0.84 (-0.82%)

USD 16.82B
IVV:AU iShares Core S&P 500 AUD

+0.42 (+0.71%)

USD 8.73B
VGS:AU Vanguard MSCI International Sh..

+0.56 (+0.42%)

USD 8.59B
QUAL:AU VanEck Vectors MSCI World ex A..

+0.44 (+0.78%)

USD 6.70B
IOZ:AU Ishares Core S&P/Asx 200

-0.28 (-0.84%)

USD 6.18B
STW:AU SPDR® S&P/ASX 200 Fund

-0.60 (-0.81%)

USD 5.58B
NDQ:AU Betashares Nasdaq 100

+0.70 (+1.52%)

USD 5.22B
HNDQ:AU BetaShares NASDAQ 100 ETF - Cu..

+0.47 (+1.14%)

USD 4.86B
A200:AU BetaShares Australia 200

-1.11 (-0.81%)

USD 4.72B
VTS:AU Vanguard US Total Market Share..

+3.01 (+0.69%)

USD 4.71B

ETFs Containing DRUG:AU

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.46% 49% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.46% 49% F 53% F
Trailing 12 Months  
Capital Gain 16.71% 42% F 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.71% 43% F 53% F
Trailing 5 Years  
Capital Gain 38.33% 77% C+ 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.33% 77% C+ 58% F
Average Annual (5 Year Horizon)  
Capital Gain 6.97% 77% C+ 57% F
Dividend Return 8.53% 73% C 55% F
Total Return 1.56% 52% F 33% F
Risk Return Profile  
Volatility (Standard Deviation) 8.42% 63% D 92% A
Risk Adjusted Return 101.30% 96% N/A 98% N/A
Market Capitalization 0.17B 34% F 65% D

Annual Financials (AUD)

Quarterly Financials (AUD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.